Frank Torti, the President and Vant Chair of $ROIV, sold 1,400,000 shares of the company on 02-19-2026 for an estimated $38,388,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.2% of their shares of this class of stock. Following this trade, they now own 13,736,547 shares of this class of $ROIV stock.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 82 times in the past 6 months. Of those trades, 1 have been purchases and 81 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- VIVEK RAMASWAMY has made 0 purchases and 9 sales selling 6,734,097 shares for an estimated $128,337,673.
- KEITH S MANCHESTER has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- FINANCIAL LP QVT has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- DANIEL ALLEN GOLD has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- FRANK TORTI (President and Vant Chair) has made 0 purchases and 3 sales selling 3,000,000 shares for an estimated $82,039,460.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 18 sales selling 4,428,209 shares for an estimated $76,897,178.
- MAYUKH SUKHATME (President & CIO) has made 0 purchases and 4 sales selling 1,697,140 shares for an estimated $38,507,031.
- MATTHEW GLINE (CEO) has made 1 purchase buying 3,315 shares for an estimated $49,957 and 3 sales selling 1,740,000 shares for an estimated $37,723,200.
- RICHARD PULIK (CFO) has made 0 purchases and 2 sales selling 406,731 shares for an estimated $9,122,307.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROIV Hedge Fund Activity
We have seen 248 institutional investors add shares of $ROIV stock to their portfolio, and 184 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SB INVESTMENT ADVISERS (UK) LTD removed 23,901,524 shares (-59.3%) from their portfolio in Q4 2025, for an estimated $518,663,070
- VIKING GLOBAL INVESTORS LP removed 17,151,640 shares (-72.7%) from their portfolio in Q4 2025, for an estimated $372,190,588
- UBS GROUP AG added 15,645,836 shares (+570.0%) to their portfolio in Q4 2025, for an estimated $339,514,641
- MORGAN STANLEY added 14,036,696 shares (+31.7%) to their portfolio in Q4 2025, for an estimated $304,596,303
- RUBRIC CAPITAL MANAGEMENT LP removed 11,000,000 shares (-55.0%) from their portfolio in Q4 2025, for an estimated $238,700,000
- GOLDMAN SACHS GROUP INC added 8,621,567 shares (+365.2%) to their portfolio in Q4 2025, for an estimated $187,088,003
- ASSENAGON ASSET MANAGEMENT S.A. added 6,877,348 shares (+11507.5%) to their portfolio in Q4 2025, for an estimated $149,238,451
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ROIV Congressional Stock Trading
Members of Congress have traded $ROIV stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ROIV Analyst Ratings
Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 02/10/2026
- HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
- JP Morgan issued a "Overweight" rating on 09/18/2025
- Guggenheim issued a "Buy" rating on 09/18/2025
- Leerink Partners issued a "Outperform" rating on 09/18/2025
- Jefferies issued a "Buy" rating on 09/18/2025
- Goldman Sachs issued a "Buy" rating on 09/18/2025
To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.
$ROIV Price Targets
Multiple analysts have issued price targets for $ROIV recently. We have seen 8 analysts offer price targets for $ROIV in the last 6 months, with a median target of $31.0.
Here are some recent targets:
- Douglas Tsao from HC Wainwright & Co. set a target price of $33.0 on 02/10/2026
- Samantha Semenkow from Citigroup set a target price of $35.0 on 02/10/2026
- Yatin Suneja from Guggenheim set a target price of $30.0 on 02/09/2026
- Corinne Jenkins from Goldman Sachs set a target price of $33.0 on 12/15/2025
- David Risinger from Leerink Partners set a target price of $32.0 on 12/15/2025
- Brian Cheng from JP Morgan set a target price of $20.0 on 09/18/2025
- Chi Fong from B of A Securities set a target price of $16.5 on 09/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
